AYLA

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ayala Pharmaceuticals (AYLA – Research Report), with a price target of $18.00. The company's shares closed last Wednesday at $1.84, close to its 52-week low of $1.75. According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -45.1% and a 7.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Inovio Pharmaceuticals, and Aquestive Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ayala Pharmaceuticals with a $13.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reiterates-a-buy-rating-on-ayala-pharmaceuticals-ayla?utm_source=advfn.com&utm_medium=referral